Celltrion said on the 26th that the post hoc analysis results of the global phase 3 clinical trial of Zympentra, the subcutaneous (SC) formulation of the autoimmune disease treatment Remsima (infliximab), were published in an international journal.
The analysis is a post hoc result from the LIBERTY-CD clinical trial conducted in patients with Crohn's disease, and was published in Clinical Gastroenterology and Hepatology, an SCI-level journal. The journal ranks in the top 6% of international journals in the field based on impact factor.
The LIBERTY-CD phase 3 clinical trial evaluated the efficacy (effect) and safety (whether adverse events occurred) of Zympentra for up to 102 weeks in 343 patients with Crohn's disease.
According to the post hoc analysis, the group of patients who maintained infliximab SC for one year showed a significant treatment effect versus placebo regardless of the location of inflammation. Consistent effects were observed across all inflammatory sites, from small-intestine–type Crohn's disease to the terminal ileum, colon, and rectum.
The company said this result differentiates it from existing Crohn's disease treatments, which show varying effects depending on the location of inflammation.
A Celltrion official said, "This study will serve as important evidence for establishing future treatment strategies for the infliximab SC formulation and for clinicians in choosing a therapy."